.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

McKinsey
Baxter
Johnson and Johnson
Daiichi Sankyo
Chubb
Deloitte
Fuji
US Department of Justice
Julphar
Express Scripts

Generated: July 26, 2017

DrugPatentWatch Database Preview

Claims for Patent: ► Subscribe

« Back to Dashboard

Claims for Patent: ► Subscribe

Title:Methods of using ALK inhibitors
Abstract: The invention provides methods for using compounds of Formula (I) for treating an EML4-ALK.sup.+ mediated condition such as EML4-ALK.sup.+ non-small cell lung cancer, and optionally resistant to crizotinib; wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5 and R.sup.6 are as defined above.
Inventor(s): Li; Nanxin (San Diego, CA), Harris; Jennifer Leslie (San Diego, CA), McNamara; Peter (San Diego, CA), Sun; Fangxian (Melrose, MA)
Assignee: IRM LLC (Hamilton, BM)
Application Number:13/981,046
Patent Claims: 1. A method for treating EML4-ALK.sup.+ mediated non-small cell lung cancer that is optionally resistant to crizotinib, comprising administering to a cell or subject a compound of Formula (I) ##STR00009## or a pharmaceutically acceptable salt thereof; wherein R.sup.1 is halo; R.sup.2 is H; or wherein R.sup.1 and R.sup.2 together with the carbon atoms to which they are attached form a 5-6 membered heteroaryl comprising 1-2 heteroatoms selected from N, O and S; R.sup.3 is SO.sub.2R.sup.7 wherein R.sup.7 is C.sub.1-6 alkyl; R.sup.4 is C.sub.1-6 alkoxy; R.sup.5 is piperidinyl optionally substituted with C.sub.1-6 alkyl; R.sup.6 is C.sub.1-6 alkyl; or R.sup.5 and R.sup.6 together with the carbon atoms to which they are attached form a 5-6 membered heterocyclic ring comprising having 1-2 heteroatoms selected from N, O and S.

2. The method according to claim 1, wherein the EML4-ALK.sup.+ mediated non-small cell lung cancer is resistant to crizotinib.

3. The method of claim 1, wherein R.sup.1 in Formula (I) is chloro.

4. The method of claim 1, wherein R.sup.4 in Formula (I) is isopropoxy.

5. The method of claim 1, wherein R.sup.5 and R.sup.6 together with the carbon atoms to which they are attached form --CH.sub.2--NR.sup.8--C(O)--, wherein R.sup.8 is hydrogen or piperidinyl, optionally substituted with C.sub.1-6 alkyl.

6. The method of claim 1, wherein said compound of Formula (I) is selected from the group: 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propa- ne-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-2-yl)phenyl)-N4-(2-(isopr- opylsulfonyl)phenyl)pyrimidine-2,4-diamine; (S)-5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-2-yl)phenyl)-N4-(2-(i- sopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; (R)-5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-2-yl)phenyl)-N4-(2-(i- sopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-3-yl)phenyl)-N4-(2-(isopr- opylsulfonyl)phenyl)pyrimidine-2,4-diamine; and 6-{5-Chloro-4-[2-(propane-2-sulfonyl)-phenylamino]-pyrimidin-2-ylamino}-5- -isopropoxy-2-(1-methyl-piperidin-4-yl)-2,3-dihydro-isoindol-1-one; or a pharmaceutically acceptable salt thereof.

7. The method of claim 6, wherein said compound is 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propa- ne-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine.

8. The method of claim 6, wherein said compound is 6-{5-Chloro-4-[2-(propane-2-sulfonyl)-phenylamino]-pyrimidin-2-ylamino}-5- -isopropoxy-2-(1-methyl-piperidin-4-yl)-2,3-dihydro-isoindol-1-one.

9. The method of claim 1, wherein said subject is a human or animal subject.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

McKinsey
QuintilesIMS
Queensland Health
Harvard Business School
Colorcon
Teva
Boehringer Ingelheim
US Army
Novartis
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot